<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29058308</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2249</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical and experimental immunology</Title><ISOAbbreviation>Clin Exp Immunol</ISOAbbreviation></Journal><ArticleTitle>Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>288</StartPage><EndPage>300</EndPage><MedlinePgn>288-300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cei.13073</ELocationID><Abstract><AbstractText>Natural killer (NK) cells participate in the regulation of the immune response. However, the immunomodulatory function of NK cells in systemic lupus erythematosus (SLE) is not well understood. The aim of this study was to evaluate the regulatory function of NK cells in SLE patients and to identify the NK cells involved in the pathogenesis of this complex disease. We analysed the expression of NK receptors and co-stimulatory molecules in peripheral NK cells (CD3<sup>-</sup> CD56<sup>+</sup> ) from SLE patients, as well as the numbers of human leucocyte antigen D-related (HLA-DR)/CD11c<sup>+</sup> NK cells. In addition, NK cell regulatory function was assessed by the detection of NK cell-mediated dendritic cell (DC) lysis. We found that SLE patients showed increased numbers of immunoglobulin-like transcript 2 (ILT2)<sup>+</sup> , CD86<sup>+</sup> and CD134<sup>+</sup> NK cells. Furthermore, NK cells from SLE patients induced higher levels of DC lysis. We were able to identify a new subset of NK cells co-expressing CD11c and HLA-DR. These atypical NK cells were increased in SLE patients when compared with controls. We have identified an expanded new subset of NK cells in SLE patients. This is the first study, to our knowledge, which demonstrates that NK cells in SLE patients have an altered phenotype with a high expression of receptors characteristic of dendritic cells. Our results suggest that the impairment in the regulatory function of NK cells, together with the increased number of DC-like NK cells, could play an important role in the development of SLE and highlight the importance of NK cells as a future therapeutic target.</AbstractText><CopyrightInformation>&#xa9; 2017 British Society for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz-Gonz&#xe1;lez</LastName><ForeName>D de J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Medicina Molecular y Traslacional, Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, Facultad de Medicina, Universidad Aut&#xf3;noma de San Luis Potos&#xed;, San Luis Potos&#xed;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Martin</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Reumatolog&#xed;a e Inmunolog&#xed;a, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n 'Salvador Zubir&#xe1;n', Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layseca-Espinosa</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medicina Molecular y Traslacional, Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, Facultad de Medicina, Universidad Aut&#xf3;noma de San Luis Potos&#xed;, San Luis Potos&#xed;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baranda</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unidad de Reumatolog&#xed;a y Osteoporosis, Hospital Central 'Ignacio Morones Prieto', San Luis Potos&#xed;, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abud-Mendoza</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Reumatolog&#xed;a y Osteoporosis, Hospital Central 'Ignacio Morones Prieto', San Luis Potos&#xed;, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcocer-Varela</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Reumatolog&#xed;a e Inmunolog&#xed;a, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n 'Salvador Zubir&#xe1;n', Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Amaro</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medicina Molecular y Traslacional, Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, Facultad de Medicina, Universidad Aut&#xf3;noma de San Luis Potos&#xed;, San Luis Potos&#xed;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsiv&#xe1;is-Urenda</LastName><ForeName>A E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-9962-4531</Identifier><AffiliationInfo><Affiliation>Medicina Molecular y Traslacional, Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, Facultad de Medicina, Universidad Aut&#xf3;noma de San Luis Potos&#xed;, San Luis Potos&#xed;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Exp Immunol</MedlineTA><NlmUniqueID>0057202</NlmUniqueID><ISSNLinking>0009-9104</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039521">CD11c Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019002">CD56 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006681">HLA-D Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039521" MajorTopicYN="N">CD11c Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019002" MajorTopicYN="N">CD56 Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006681" MajorTopicYN="N">HLA-D Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016131" MajorTopicYN="N">Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">atypical NK cell</Keyword><Keyword MajorTopicYN="N">dendritic cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29058308</ArticleId><ArticleId IdType="pmc">PMC5801498</ArticleId><ArticleId IdType="doi">10.1111/cei.13073</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caligiuri MA. Human natural killer cells. Blood 2008; 112:461&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2481557</ArticleId><ArticleId IdType="pubmed">18650461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer&#x2010;cell subsets. Trends Immunol 2001; 22:633&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11698225</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002; 10:147&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors. From molecules and cells to clinical relevance. Immunol Res 2006; 35:263&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014; 92:221&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24366519</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004; 64:215&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457:557&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674434</ArticleId><ArticleId IdType="pubmed">19136945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama M, Takeda K, Kawano M, Takai T, Ishii N, Ogasawara K. Natural killer (NK)&#x2010;dendritic cell interactions generate MHC class II&#x2010;dressed NK cells that regulate CD4+ T cells. Proc Natl Acad Sci USA 2011; 108:18360&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215013</ArticleId><ArticleId IdType="pubmed">22042851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross&#x2010;talk between activated human NK cells and CD4+ T cells via OX40&#x2013;OX40 ligand interactions. J Immunol 2004; 173:3716&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15356117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol 2004; 25:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">14698284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerosa F, Baldani&#x2010;Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195:327&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193595</ArticleId><ArticleId IdType="pubmed">11828007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg N, Berggren O, Leonard D et al IFN&#x2010;alpha production by plasmacytoid dendritic cells stimulated with RNA&#x2010;containing immune complexes is promoted by NK cells via MIP&#x2010;1beta and LFA&#x2010;1. J Immunol 2011; 186:5085&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21430220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG. Targeting of human dendritic cells by autologous NK cells. J Immunol 1999; 163:6365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10586025</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Baratin M, Chiche L et al Induction of B7&#x2010;H6, a ligand for the natural killer cell&#x2010;activating receptor NKp30, in inflammatory conditions. Blood 2013; 122:394&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">23687088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlazzo G, Morandi B, D'Agostino A et al The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 2003; 33:306&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlazzo G, Semino C, Melioli G. HLA class I molecule expression is up&#x2010;regulated during maturation of dendritic cells, protecting them from natural killer cell&#x2010;mediated lysis. Immunol Lett 2001; 76:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11222911</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi PP, Roberts PC, Wolf NA, Swanborg RH. NK cells inhibit T cell proliferation via p21&#x2010;mediated cell cycle arrest. J Immunol 2005; 174:4590&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15814681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N, &#xd8;dum N, Urs&#xf8; B, Lanier LL, Spee P, Sandberg JK. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA&#x2010;1 and TRAIL and dampened via CD94/NKG2A. PLOS ONE 2012; 7:31959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284517</ArticleId><ArticleId IdType="pubmed">22384114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK et al Systemic lupus erythematosus. Nat Rev Dis Primers 2016; 2:16039.</Citation><ArticleIdList><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. J Leukoc Biol 2015; 98:479&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z, Ma N, Zhao L, Jiang ZY, Jiang YF. Differential expression of natural killer activating and inhibitory receptors in patients with newly diagnosed systemic lupus erythematosus. Int J Rheum Dis 2016; 19:613&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24617980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B, Beziat V, Haroche J et al Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon&#x2010;gamma production in patients with active disease. Arthritis Rheum 2011; 63:1698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">21370226</ArticleId></ArticleIdList></Reference><Reference><Citation>Voynova EN, Skinner J, Bolland S. Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus. J Immunol 2015; 194:1503&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323852</ArticleId><ArticleId IdType="pubmed">25595787</ArticleId></ArticleIdList></Reference><Reference><Citation>Voynova E, Qi CF, Scott B, Bolland S. Cutting edge: induction of inflammatory disease by adoptive transfer of an atypical NK cell subset. J Immunol 2015; 195:806&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570026</ArticleId><ArticleId IdType="pubmed">26109646</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB et al Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol 2000; 61:721&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10980383</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CW, Crafton E, Fan HN et al Interferon&#x2010;producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12:207&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">16444266</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranami T, Miyake S, Yamamura T. Differential expression of CD11c by peripheral blood NK cells reflects temporal activity of multiple sclerosis. J Immunol 2006; 177:5659&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015755</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Teixeira L, Ines L et al NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clin Rheumatol 2013; 32:805&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">23377197</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YW, Kee SJ, Cho YN et al Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">19479851</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002; 46:1763&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124859</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibatomi K, Ida H, Yamasaki S et al A novel role for interleukin&#x2010;18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001; 44:884&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11315928</ArticleId></ArticleIdList></Reference><Reference><Citation>Favier B, Lemaoult J, Lesport E, Carosella ED. ILT2/HLA&#x2010;G interaction impairs NK&#x2010;cell functions through the inhibition of the late but not the early events of the NK&#x2010;cell activating synapse. FASEB J 2010; 24:689&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19841038</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsivais&#x2010;Urenda A, Nino&#x2010;Moreno P, Abud&#x2010;Mendoza C et al Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR&#x2010;1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 2007; 29:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17601702</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz&#x2010;Aviles G, Tamayo&#x2010;Legorreta E, Cruz&#x2010;Valdez A et al Prevalence of antibodies against cytomegalovirus in women of reproductive age. Salud Publica Mex 1993; 35:20&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8385805</ArticleId></ArticleIdList></Reference><Reference><Citation>Guma M, Budt M, Saez A et al Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus&#x2010;infected fibroblasts. Blood 2006; 107:3624&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16384928</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JH, Horowitz A, Mehrabi M et al A distinct subset of human NK cells expressing HLA&#x2010;DR expands in response to IL&#x2010;2 and can aid immune responses to BCG. Eur J Immunol 2011; 41:1924&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549558</ArticleId><ArticleId IdType="pubmed">21491418</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano N, Endoh M, Nomoto Y, Sakai H, Rifai A. Increase of HLA&#x2010;DR&#x2010;positive natural killer cells in peripheral blood from patients with IgA nephropathy. Hum Immunol 1996; 49:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8839777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of T cell co&#x2010;stimulation and co&#x2010;inhibition. Nat Rev Immunol 2013; 13:227&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Luo G, Zhou J et al CD86 is an activation receptor for NK cell cytotoxicity against tumor cells. PLOS ONE 2013; 8:e83913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859666</ArticleId><ArticleId IdType="pubmed">24349559</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft M. Control of immunity by the TNFR&#x2010;related molecule OX40 (CD134). Annu Rev Immunol 2010; 28:57&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882161</ArticleId><ArticleId IdType="pubmed">20307208</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquemin C, Schmitt N, Contin&#x2010;Bordes C et al OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity 2015; 42:1159&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570857</ArticleId><ArticleId IdType="pubmed">26070486</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G, Kavanagh D, Rihn S et al IL&#x2010;10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J Clin Invest 2010; 120:1905&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877944</ArticleId><ArticleId IdType="pubmed">20440075</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiesa MD, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell&#x2010;mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig&#x2010;like receptors. Eur J Immunol 2003; 33:1657&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa Y, Screpanti V, Yagita H et al NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 2004; 172:123&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14688317</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Karaksy SM, Kholoussi NM, Shahin RM, El&#x2010;Ghar MM, Gheith Rel S. TRAIL mRNA expression in peripheral blood mononuclear cells of Egyptian SLE patients. Gene 2013; 527:211&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23792015</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>